Press Release

NeoGenomics Raises Guidance and Projects 30% Year-Over-Year Revenue Growth in Quarter 2, 2014

NeoGenomics Schedules its Q2 2014 Earnings Release for July 17, 2014

NeoGenomics Selected by Aurora Diagnostics as Primary Partner for Molecular, FISH, and Immunohistochemistry Testing

NeoGenomics Reports Revenue of $18.2 Million and Adjusted EBITDA of $1.7 million for the First Quarter

NeoGenomics Schedules its Q1 2014 Earnings Release for April 23, 2014

NeoGenomics Announces Next Generation Sequencing Tests for Solid Tumor Cancers and Myelodysplastic Syndrome

NeoGenomics Reports Record Revenue of $18.3 Million, Adjusted EBITDA of $2.7 Million and Net Income of $0.02 per Share for the Fourth Quarter 2013

NeoGenomics Launches 22 New Cancer Genomic Tests Designed for Actionable Profiling of Various Hematologic and Solid Cancers

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients